The Clinical Application Of CT Guided Interstitial¹²⁵-I Seeds Implantation For Treatment Of Metastatic Retroperitoneal Tumor

Objective: To evaluate the clinical application value of computed tomography （CT） guidedinterstitial¹²⁵-I seeds implantation for treating metastatic retroperitoneal tumor.Material and Method: Between December2010and February2012,32patients with metastaticretroperitoneal tumor were included （21males，11femalesï¼›median age，57years old：range from29to82）.Based on the origin and treatment method, the tumors were divided into9groups, including hepatocellularcarcinoma （HCC）9, pancreatic carcinoma7, colon carcinoma3, ovary carcinoma2, esophagus carcinoma2, and bone sarcoma1. All the postoperative metastasis were confirmed by different imaging equipment.Based on the metastatic tumor sites, they were divided into5group: metastases around the pancreas16,near the para-aortic2, in the hilar5, in the rear of the kidney2, between liver and stomach6. Three gradeWHO classification of pain were used （grade I5, grade II16and grade III11）. All of them wererefractory to anodyne and were received the percutaneous CT guided interstitial¹²⁵-I seeds implantationtreatment. The efficacy of¹²⁵-I seeds implantation treatment was judged by the international pain efficacycriteria. Excellent was defined as that the pain disappeared or classification standard decreased by twolevels; Effective: the pain grading standards declined by one level; Invalid: the pain grading standard didnot decline or increased. The mass size was judged by the international standards of tumor treatment, whichwere divided into complete remission （CR）, partial response （PR）, no change （NC） and progress disease（PD）.Result：Through a week of treatment, the excellent, effective and invalid result of pain are17,9and6separately, with the efficacy rate of81.13%;1months after the treatment, the excellent, effective andinvalid result of pain are22,7and3separately, with the efficacy rate of90.63%;3months after thetreatment, the excellent, effective and invalid result of pain are26,5and1separately, with the efficacy rateof96.88%; and6months after the treatment, the excellent, effective and invalid result of pain are23,6and3separately, with the efficacy rate of90.63%. Besides,1month after the treatment, the CR, PR, NC andPD result of mass size are8,18,6and0separately, with the efficacy rate of81.25%;3month after thetreatment, the CR, PR, NC and PD result of mass size are9,19,3and1separately, with the efficacy rate of 87.50%（one patient died）; and6month after the treatment, the CR, PR, NC and PD result of mass size are13,17,0and2separately, with the efficacy rate of93.75%..Conclusion：The percutaneous CT guided interstitial¹²⁵-I seeds implantation is a feasible, safe,effective and microinvasive treatment for metastatic retroperitoneal tumor, and is an effective method ofcontrolling pain and inhibiting growth of metastatic tumor, especially for the patients with pain of level Iand II.